A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
Winnie Yeo(Chinese University of Hong Kong), Philip J. Johnson(Prince of Wales Hospital), Paul B.S. Lai(Chinese University of Hong Kong), Thomas W. T. Leung(Chinese University of Hong Kong), Simon C.H. Yu(National Yang Ming Chiao Tung University), Wan Yee Lau(Chinese University of Hong Kong), Benny Zee(Chinese University of Hong Kong), Tony Mok(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Brigette Ma(Chinese University of Hong Kong), Amanda M. Y. Tang(Chinese University of Hong Kong), Pun Hui(Chinese University of Hong Kong), Kwok Chi Lam(Chinese University of Hong Kong), Wing Ming Ho(Chinese University of Hong Kong), Frankie Mo(Chinese University of Hong Kong), Herman Wong(Chinese University of Hong Kong), Jane Koh(Chinese University of Hong Kong)
Cited by 591
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k